Poster Oral Presentation 2

[PO-012] Etrasimod efficacy in patients with mildly to moderately active ulcerative colitis (modified Mayo score 4–6) in the phase 3 ELEVATE UC clinical program

Dana Verbovsky, Andres J Yarur¹, Geert R D'Haens², Filip Baert³, Martina Goetsch⁴, Chuanbo Zang⁵, Guibao Gu⁶, Rafal Mazur⁴, Michael Keating⁷, Elizabeth Kudlacz⁸, Sarah Sidhu⁷, *Karolina Wosik⁹, Silvio Danese¹⁰ (1. Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 2. Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands, 3. Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 4. Pfizer AG, Zürich, Switzerland, 5. Pfizer Inc, Collegeville, PA, USA, 6. Pfizer Inc, La Jolla, CA, USA, 7. Pfizer Inc, New York, NY, USA, 8. Pfizer Inc, Groton, CT, USA, 9. Pfizer Canada, Kirkland, QC, Canada, 10. Division of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.